Oppenheimer Starts Climb Bio (CLYM) at Outperform,. PT $10

Oppenheimer analyst Leland Gershell initiates coverage on Climb Bio (NASDAQ: CLYM) with a Outperform rating and a price target of $10.00.

The analyst comments "We initiate coverage of Climb Bio with an Outperform rating and $10 price target. Lead candidate IV budoprutug drives our enthusiasm as this prospective best-in-class anti-CD19 antibody advances for several poorly-met autoimmune conditions. An encouraging efficacy signal in patients with pMN (can lead to kidney failure) makes us optimistic for a soon-to-begin Phase 2, and initial trials in ITP (a bleeding disorder) and lupus should begin imminently. We see $1B+ sales potential across these indications, and a subcutaneous version positioned for at-home administration offers upside optionality. Anti-APRIL antibody CLYM116 is slated to enter the clinic for IgAN (also can lead to kidney failure) in early 2026. With shares seemingly reflecting little credit for opportunities and through-2027E cash runway (~$180M), we recommend investors build a position."

For an analyst ratings summary and ratings history on Climb Bio click here. For more ratings news on Climb Bio click here.

Shares of Climb Bio closed at $1.24 yesterday.

You May Also Be Interested In

• H.C. Wainwright Reiterates Buy Rating on Climb Bio (CLYM)
• Cantor Fitzgerald Starts Silence Therapeutics (SLN) at Overweight
• H.C. Wainwright Reiterates Buy Rating on ProMIS Neurosciences (PMN)